Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Separate FDA Post-Market Drug Safety Office Outlined In Approps Bill Report

This article was originally published in The Pink Sheet Daily

Executive Summary

House subcommittee would provide FDA with $55 million more than the amount requested in President Obama's FY 2011 budget proposal.

You may also be interested in...



Separate FDA Safety Office Attached To House Report, Still Faces Steep Road

A proposal to establish an independent post-market drug surveillance office at FDA will face tough sledding if it comes up in the House Energy and Commerce Health Subcommittee.

Separate FDA Safety Office Attached To House Report, Still Faces Steep Road

A proposal to establish an independent post-market drug surveillance office at FDA will face tough sledding if it comes up in the House Energy and Commerce Health Subcommittee.

FDA Expects Sharp Drop In Fee-Paying Drug Applications This Year

In what could be viewed as an ominous sign of declining pharmaceutical R&D productivity, FDA is predicting a sharp drop-off in fee-paying drug and biologic applications in the current fiscal year

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS070845

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel